Barclays PLC cut its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 50.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 393,418 shares of the company's stock after selling 407,984 shares during the quarter. Barclays PLC owned approximately 0.72% of LivaNova worth $20,671,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in LIVN. Fifth Third Bancorp grew its holdings in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after acquiring an additional 332 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in LivaNova in the second quarter valued at approximately $88,000. Central Pacific Bank Trust Division purchased a new position in LivaNova in the third quarter valued at approximately $178,000. TradeLink Capital LLC purchased a new position in LivaNova in the second quarter valued at approximately $208,000. Finally, Captrust Financial Advisors acquired a new stake in LivaNova during the third quarter worth approximately $217,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by insiders.
LivaNova Stock Performance
Shares of LIVN traded down $0.61 during mid-day trading on Friday, hitting $51.50. 515,221 shares of the company's stock were exchanged, compared to its average volume of 610,064. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The business's 50 day moving average is $51.97 and its two-hundred day moving average is $51.43. The firm has a market capitalization of $2.80 billion, a P/E ratio of 122.62 and a beta of 0.98.
Wall Street Analyst Weigh In
LIVN has been the subject of several research analyst reports. Needham & Company LLC restated a "buy" rating and issued a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. Robert W. Baird lifted their target price on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Baird R W raised LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. Finally, StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 16th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $69.17.
View Our Latest Stock Analysis on LIVN
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
